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Transmission dynamic models linked to economic analyses often form part of the
decision making process when introducing new chlamydia screening interventions.
Outputs from these transmission dynamic models can vary depending on the values
of the parameters used to describe the infection. Therefore these values can have an
important influence on policy and resource allocation. The risk of progression from
infection to pelvic inflammatory disease has been extensively studied but the
parameters which govern the transmission dynamics are frequently neglected. We
conducted a systematic review of transmission dynamic models linked to economic
analyses of chlamydia screening interventions to critically assess the source and
variability of the proportion of infections that are asymptomatic, the duration of
infection and the transmission probability. We identified nine relevant studies in
Pubmed, Embase and the Cochrane database. We found that there is a wide
variation in their natural history parameters, including an absolute difference in the
proportion of asymptomatic infections of 25% in women and 75% in men, a six-fold
difference in the duration of asymptomatic infection and a four-fold difference in the
per act transmission probability. We consider that much of this variation can be
explained by a lack of consensus in the literature. We found that a significant
proportion of parameter values were referenced back to the early chlamydia literature,
before the introduction of nucleic acid modes of diagnosis and the widespread testing of
asymptomatic individuals. In conclusion, authors should use high quality contemporary
evidence to inform their parameter values, clearly document their assumptions and make
appropriate use of sensitivity analysis. This will help to make models more transparent
and increase their utility to policy makers.
Keywords: Chlamydia trachomatis, Mathematical modelling, Systematic review,
Natural history, ScreeningBackground
Chlamydia screening programmes have been implemented with the aim of reducing
the incidence and prevalence of infection and its complications [1,2]. As there are few
randomised controlled trials (RCTs) looking at the impact of screening on these out-
comes, [3] transmission dynamic models are used to provide insight into their likely
impact [4,5]. Estimates from these models, such as the number of infections over time,
are frequently used in economic models (often in the form of a decision tree) to assess© 2014 Davies et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
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dynamic economic models are an important source of evidence for policy makers.
Transmission dynamic models capture not only the direct effects of screening (i.e.
the number of individuals screened, diagnosed and treated) but also the indirect effect
of reduced onward transmission [6]. A key concept in infectious disease dynamics is
the ‘basic reproduction number’ (R0); the average number of new infections arising
from an infected individual in a wholly susceptible population [7]. It is determined by
both population level factors and biological factors specific to the organism and is the
product of the probability of transmission between an infected person and an unin-
fected person (β), the contact rate between infected and susceptible people (c) and the
duration of infection (D).
Despite this fundamental role in infection transmission dynamics, there is widely
acknowledged uncertainty in the parameters used to calculate R0 for chlamydia [8-10].
This means that the predicted impact of a chlamydia screening intervention can be
altered under different but similarly plausible assumptions about for example, the
untreated duration of infection or the proportion of infections that are asymptomatic
[10,11]. To improve the interpretation of the results from a model it is important to
consider how the assumptions used in the study compare to the full range of plausible
input values.
In this study we focus on transmission dynamic models embedded within economic
analyses. We will consider the representation of the biological characteristics of chla-
mydia that are central to modelling its transmission in a population, and that ultimately
influence the predicted success of interventions. Specifically, we aim to critically assess
the source and variability of the proportion of infections that are asymptomatic, the
duration of infection and the transmission probability to increase model transparency
and improve understanding of the current level of knowledge on the biological features
determining the transmission of chlamydia.Methods
We searched Pubmed, Embase and the Cochrane database between 01/01/2004 and
29/05/2013 using a search strategy based on a published systematic review of economic
evaluations of chlamydia screening [12]. For full details of the search methodology see
additional information (Additional file 1). To be included in this review, studies must
contain a transmission dynamic model linked to an economic model that considers
women in a general population setting, any chlamydia screening intervention and at
least one adverse reproductive outcome in women. The search was limited to models
with an economic component as they are formulated to directly inform the policy
making process (such studies must include at least one reproductive outcome in order
to estimate the potential health benefits from screening). Non-English language and
non-human studies, abstracts, letters and editorials were excluded.
References were imported to an Endnote library where duplicates were identified
based on author, title and year of publication followed by a manual search for
additional duplicates. One author (BD) screened the titles, abstracts and full manu-
scripts, where necessary, to identify studies for inclusion. Two authors (SA and BD)
reviewed the reference lists of included articles for relevant studies and extracted
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meter source. We limited the natural history parameters to those which influence the
transmission dynamic component of the model. Other parameters, including those
which determine the likelihood of later complications, have been reviewed elsewhere
and were beyond the scope of this review [13]. For each study included in the review,
we obtained the references for the natural history parameters and the references cited
within these studies (if they were not original studies) until the underlying reference
was identified.
We present a descriptive analysis of the natural history parameters and a critical
review of the quality and appropriateness of the cited sources. For the proportion of
infections which are asymptomatic in women, we constructed a flowchart depicting the
pathway of references used to inform the assumption in each of the studies included in
this review. Within this figure, we classified the studies as either “primary” studies if
they generated new data or “review or modelling” studies if they were based on existing
data. We also identified the primary studies that had a suitable design for informing
this parameter (defined as a study looking at a population of women not selected on
the basis of symptoms who were tested for chlamydia) and presented a parameter
value.Results
The initial search identified 629 papers of which 9 met the inclusion criteria
[5,6,14-20]. We also included two studies from the systematic review we based our
search strategy on that met the inclusion criteria for this study [21,22] (Figure 1). These
eleven studies included two sets of publications from research groups that use the same
dynamic model and parameter values [6,16,17,22]. To avoid over-representing the
methods of these authors we have combined the parameter information from each setExcluded on title, abstract or full text 
N=620
Duplicates = 178
Not genital chlamydia in women = 195 
Not general population setting =24 
Not chlamydia screening = 135 
Not economic study = 65
No transmission dynamic model = 23
Studies identified in database search
Pubmed = 270
Embase = 324
Cochrane = 35
Studies that met inclusion criteria
N= 9
Included from 
previous 
systematic 
review
N= 2
Included studies
N= 11
Figure 1 Identification of eligible studies.
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Therefore we present our analysis of nine studies with independent parameter esti-
mates [5,14,15,17-22].
All the studies included in this review consider the cost-effectiveness of hypothetical
chlamydia screening programmes or modifications to existing control strategies in de-
veloped countries (Table 1). Six of these nine studies [5,14,15,18,19,22] use an individ-
ual based transmission dynamic model and the remaining three [17,20,21] use a
compartmental model. Two of the nine studies [17,21] developed a novel transmission
dynamic model and 7 studies [5,14,15,18-20,22] are based on one of three previously
published transmission dynamic models, Fisman et al. [20,23]; Kretzschmar et al.
[4,5,15,19,22] and Turner et al. [14,18,24]. The values of key parameters used in the in-
cluded studies are given in Table 1. Figure 2 provides an illustration of the reference
pathway for the proportion of infections that are asymptomatic in women
[4,5,14,15,17-22,24-47]; the reference pathway for all three parameters, in men and
women, is provided in the additional information (Additional file 2).
All nine studies assume a sex difference in the proportion of the population who de-
velop symptoms following infection. In three of the nine studies, men have a higher
proportion of infections that are asymptomatic (92-100% compared to 90–95.5% in
women) [14,18,20]. Two of this group of three studies [14,18] share a common source
for this parameter, the modelling study by Turner et al., [24] where the proportion of
infections that are asymptomatic is obtained through model fitting (Figure 2). The
other study in this group of three [20] references a variety of studies [25-27]. The
remaining six studies assume that between 70-75% of infections in women are asymp-
tomatic [5,15,17,19,21,22]. Four of these six assume that 50% of infections in men are
asymptomatic [15,17,21,22] and two assume that 25% of infections in men are asymp-
tomatic [5,19]. The modelling study by Kretzschmar et al. is referenced as the sole
source of this parameter in three of the six studies [4,5,15,19] while the remaining three
studies [17,21,22] reference a variety of studies [28-32,49].
For the duration of infection, seven of the nine studies define it for symptomatic or
asymptomatic infection [5,15,17-19,21,22] and two define it for treated or untreated in-
fection [14,20]. For the purposes of this comparison, when discussing duration of infec-
tion we have included estimates of the duration in treated individuals in the
‘symptomatic’ category and estimates of the duration in untreated individuals in the
‘asymptomatic’ category, although we recognise that this is an assumption. Five of the
nine studies assume no sex difference in the duration of infection, [14,17,18,20,21] two
assume a sex difference in the duration of symptomatic infection [5,19] and two as-
sume a sex difference in the duration of symptomatic and asymptomatic infections
[15,22]. Where a sex difference is assumed, infection is always stated to last longer in
women. In eight of the nine studies, asymptomatic infection is estimated to last be-
tween 180–370 days in women and 180–200 days in men [5,14,15,17-20,22]. In the
remaining study, the duration of asymptomatic infection is stated to be around
2–3 years [21]. The duration of symptomatic infection ranges between 30–40 days in
women and 30–33 days in men in the seven studies where this parameter is presented
[5,14,15,17-19,22].
Adams and Gillespie [14,18] assume the shortest duration of symptomatic and
asymptomatic infection and are based on the model by Turner et al. where the
Table 1 Description of included studies
Study Setting TD model structure
and source
Screening uptake
source
Baseline chlamydia
prevalence source
Proportion
asymptomatic
Duration of infection Risk of transmission
(baseline)No
symptoms
Symptoms
Adams et al.
2007 [14]
Comparison of
screening strategies, UK
Individual based,
Turner et al. [24]
Studies of
opportunistic
screening, England
Systematic review
and UK survey data
95.5% women;
100% men
180 days not
seeking
treatment
30 days
seeking
treatment
0.0375 per act
Andersen et al.
2006 [15]
Home sampling
screening with partner
notification, Denmark
Individual based,
Kretzschmar et al. [4,48]
RCT of home
sampling, Aarhus
Danish surveillance
system and observational
study in Aarhus
70% women;
50% men
370 days in
women;
200 days in men
40 days in
women;
33 days in men
0.11 per act
de Vries et al.
2006 [17]
One off screening,
the Netherlands
Compartmental,
original model
Pilot of one off
screening, the
Netherlands
Pilot of one off
screening, the
Netherlands
70% women;
50% men
1 year 1 month 0.68 assume per
partnership
de Vries et al.
2008 [16]
Repeat systematic
screening, the
Netherlands
As above As above As above As above As above As above As above
Gillespie et al.
2012 [18]
Opportunistic screening,
Ireland
Individual based,
Turner et al. [24]
Pilot of
opportunistic
screening, Ireland
UK data 95.5% women;
100% men
180 days 30 days 0.0375 per act
Low et al.
2007 [5]
Active screening, UK Individual based,
Kretzschmar et al. [4,48]
ClaSS cross sectional
study of screening
uptake
ClaSS project 70% women;
25% men
200 days 40 days in women;
33 days in men
0.122 per act female
to male;
0.154 per act
male to female
Roberts et al.
2007 [19]
Register based
screening, England
Individual based,
Kretzschmar et al.
and Low et al. [4,5,48]
ClaSS cross sectional
study of screening
uptake
ClaSS project 70% women;
25% men
200 days 40 days in women;
33 days in men
0.061 per day female
to male;
0.077 per day male
to female
Townshend
and Turner
2000 [21]
Three different
screening strategies, UK
Compartmental,
original model
Not presented Sample of women
presenting for cervical
smear, UK
75% women;
50% men
2-3 years Not presented Not presented
Tuite et al.
2012 [20]
Screening, Canada Compartmental,
Fisman et al. [23]
Testing patterns
from Ontario Public
Health Laboratory
Annual notifiable
disease data, Canada
90% women;
92% men
1 year untreated Not presented Present per partnership
transmission probability*
partner change rate
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Table 1 Description of included studies (Continued)
Welte et al.
2000 [22]
GP based opportunistic
screening, Netherlands
Individual based,
Kretzschmar et al. [4,48]
GP pilot study,
Amsterdam
GP pilot study,
Amsterdam
70% women;
50% men
Not presented Not presented 0.10 per act
Welte et al.
2005 [6]
As above As above As above As above Not stated,
assume as
above
370 days in
women;
200 days in men
40 days in
women;
33 days in men
0.11 per act
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Figure 2 Illustration of reference pathway for “proportion of infections that are asymptomatic
in women”.
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[24,50,51]. Andersen, Low, Roberts and Welte [5,15,19,22] base their durations on the
model by Kretzschmar et al. [4] who referenced prospective cohorts by Buhaug et al.
[52] and Rahm et al. [33] for the duration of asymptomatic infection in women while
the remaining durations (symptomatic infection in women; asymptomatic infection in
men; symptomatic infection in men) were taken from a technical report by van de Laar
et al. and based on studies of gonorrhoea as there is no equivalent data for chlamydia
[53]. De Vries and Tuite use one year as the duration of asymptomatic infection in
women [17,20] based on a cost-effectiveness study by Buhaug et al. and a review by
Geisler et al. [9,54]. One study does not reference this parameter [21].
Five of the nine studies in this review use a per act transmission probability of
between 0.0375 and 0.154 [5,14,15,18,22]. Of these five studies, the two [14,18] that use
the lowest value of 0.0375 cited the modelling study by Turner et al. who obtained their
value by fitting model prevalence to prevalence data [24]. The other three of these five
studies [5,15,22] cite the modelling study by Kretzschmar et al. who estimated that the
upper bound for the per act transmission probability is 0.108, (calculated from a
Sexually Transmitted Infection (STI) clinic study of concordance in partnerships by
Quinn et al.) [4,55,56]. Of the four remaining studies, one [17] uses data from the same
study by Quinn et al. and a per partnership transmission probability of 0.68 [56], one
uses a per day transmission probability based on the model of Kretzschmar et al. [4,19]
and two do not explicitly state the value used for this parameter [20,21]. Of the seven
studies that present the risk of transmission, two assume a sex difference with a higher
risk from male to female [5,19].
The majority of the studies (8 out of 9) perform a sensitivity analysis [5,14,15,18-22].
However these often focus on intervention related parameters (including the proba-
bility of accepting a screen [5,14,18-22], level of partner notification [15,22], efficacy of
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history parameters considered in this review are often estimated through model fitting
or calibration to prevalence or incidence data and the final values used in the models
are sometimes not stated.
The quality of referencing for the parameter values was variable. Multiple papers
were often cited for each parameter (Figure 2 and Additional file 2) and where it was
possible to identify the source reference, a high proportion of parameter values were
referenced back to the earlier transmission dynamic models [4,23,24]. Some references
were from clinical studies conducted before nucleic acid amplification tests (NAATs)
and widespread testing of asymptomatic individuals (e.g. Rahm et al. 1986 [33]
(duration of infection) and Zimmermann et al. 1990 [34] (proportion asymptomatic)).
Also, parameter values were often modified from the figure given in the referenced
primary study, with varying levels of detail about the rationale behind this change. For
the proportion of infections that were asymptomatic in women, we were able to access
22 of the studies that make up the reference pathways of the nine studies in this review.
Of these 22 studies, we consider that 12 were primary studies and 4 had an appropriate
design to inform estimates of this parameter.Discussion
Main findings
We found wide variation in the natural history parameters used in transmission
dynamic models of chlamydia linked to economic analyses. There was an absolute dif-
ference in the proportion of asymptomatic infections of 25% in women and 75% in
men, a six-fold difference in the duration of asymptomatic infection and a four-fold dif-
ference in the per act transmission probability. We conclude that much of this variation
can be explained by a lack of evidence or consensus in the literature as multiple sources
were often referenced for each parameter. Additionally, there was often little discussion
of how the final parameter value was chosen. This may be due to word count restric-
tions but a description of this critical process would allow readers to better critique the
appropriateness of the parameter values used and the potential generalizability of the
findings.Strengths and limitations of study
We performed a systematic search of the literature. We limited our search to English
language papers but we used broad search terms (based on an earlier systematic review)
to try and capture relevant studies. We restricted our analysis to studies with transmis-
sion dynamic models as this is the gold standard for the cost-effectiveness assessments
that are predominantly used by policy makers [12,57]. Our analysis was limited by the
availability of historic references for parameter values and by the reporting and referen-
cing of parameter values in the source publications.Role of model structure and model fitting
Model fitting is commonly used with transmission dynamic models. This is the process
of systematically varying the initial parameter values (e.g. transmission probability) until
the output of the model reflects a known parameter (e.g. chlamydia prevalence) in the
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the same model output. Model fit can be improved by fitting to more than one measure-
ment (e.g. prevalence and incidence) but when parameters are obtained through fitting,
the model output can only ever be as good as the underlying empirical estimates. Further-
more, correlation exists between certain parameters, such as the transmission probability
and duration of infection. This introduces an additional complexity as it means that
assumptions made about one variable can and will impact on the other parameter. There-
fore to fully interpret a model output it is necessary to understand the uncertainties in
each parameter, the correlation between parameters and the underlying model structure.
Meta modelling studies have shown how both model uncertainty and parameter
uncertainty can lead to disparate conclusions despite plausible baseline prevalence
estimates [10,58]. The appropriate use of sensitivity analysis can explore whether the
natural history parameters are affecting the cost-effectiveness findings or the potential
impact of the intervention. These issues surrounding model structure, fitting and
assumptions have been discussed extensively and there are guidelines available detailing
best practice for modelling studies [57].Strengths and limitations of parameter values
The majority of parameters were well referenced and appropriately sourced and we
assume that many of those without a reference were obtained through model fitting.
However we found several examples of authors citing several different sources or using
parameter values that differed from the quoted source without an adequate discussion of
the rationale behind the change. Few authors fully discussed the implications of using
parameter values from other settings despite a body of evidence describing how the epi-
demiology of chlamydia and its complications varies between regions and has changed
over time.
The overarching limitation of parameter values used in transmission dynamic models
is that they are obtained from primary studies that are not always able to measure the
underlying process that will be modelled. For example, we will never be able to mea-
sure the true duration of a chlamydia infection in an observational study, as it is the
timing of diagnosis rather than the timing of infection that is measured. The design
and conduct of the primary study may also affect how well its estimates reflect the true
situation. For example the ability of a result of a diagnostic test to measure the true
situation is limited by its sensitivity and specificity. And estimates from primary studies
may differ between settings and over time, for example due to the introduction of more
sensitive tests or a change in the risk profile of the population being tested.
Therefore there will always be uncertainty around how well the estimates from pri-
mary studies represent the true situation being modelled. In addition, these estimates
(with an uncertain relationship to the true parameter value) are then used in models
which by definition are a simplification of the real situation and may not be able to
reflect the breadth of heterogeneity in real life. With these limitations in mind, we will
go on to discuss the specific strengths and limitations of the three natural history
parameters considered in this review.
There was general agreement that asymptomatic infection is more common in
women than men (Table 2). This may reflect the true biology of chlamydia. However if
Table 2 Summary of chlamydia natural history parameters used in included studies and
suggested evidence based parameter values for future transmission dynamic models
Parameter Range used in included papers Suggested value
Proportion asymptomatic Male: 25% - 100% To be based on observed treatment
seeking rates in the modelled
population [24]Female: 70% - 95.5%
Duration of infection
a) Symptomatic Male: 30 – 33 days
30 - 33 days (consensus)
Female: 30 – 40 days
b) Asymptomatic Male: 180 days – 3 years
497 days [59]
Female: 180 days – 3 years
Risk of transmission per act 0.0375 – 0.154 male - female
0.095 (IQR 0.06 – 0.167) [60]
0.0375 – 0.122 female - male
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more opportunity to detect prevalent, and arguably asymptomatic, infections in
women. This means that if the true likelihood of having symptoms during an infection
is equal between the sexes, a longer duration of infection in women may act to increase
the number of infections that are asymptomatic at detection as a proportion of all
detected infections in women.
The commonest figures for the proportion of asymptomatic infections, 70% in
women and 50% or under in men, are from a historical contact tracing study which
used tests with low sensitivity [34]. Therefore this study may underestimate the true
proportion infected. If we are going to continue to use this parameter in models there
is a need to obtain a contemporary estimate from cases diagnosed using highly sensitive
NAATs.
However there is an alternative approach. It has been shown that using a population
specific measure of the proportion of individuals who seek treatment, rather than the
proportion of infections that are asymptomatic, can provide a better fit to observed
chlamydia prevalence [24]. Using observed data on treatment seeking behaviour by-
passes the need to make assumptions about the underlying proportion of infections
that are symptomatic and ensures that the measure is specific to the population of
interest. This is important as the proportion of infections that are symptomatic may
not be generalizable as symptom recognition may vary between populations [51].
Systematic reviews have failed to find consensus in the estimated duration of
untreated chlamydia infection [9,50,51] which may explain why a range of values are
used in the studies included in this review (from 180 days to 2–3 years). Most studies
assume a shorter duration of infection in men despite little evidence for such a dif-
ference [50]. Many authors have discussed the enormous challenges to accurately mea-
suring the duration of untreated infection, including the unknown time from infection
to diagnosis, the possibility of reinfection (with same or different strain) and length-
time bias from screening [9,50,59]. Price et al. evaluated this variation in duration of
infection using a mathematical model and predicted that there are several classes of
infection that clear at different rates [59]. They estimate that the overall mean duration
of untreated infection is 1.36 years (497 days) (95% CI 413–595 days). This is longer
than the previously assumed 1 year median duration reported by a systematic review
[9] but similar to the estimate of 433 days (95% CI 420–447) from a modelling study
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evidence than historical clinic-based studies alone, then the majority of the studies in this
review have truncated the true duration of untreated infection. This may have led to an
underestimation of the predicted impact of the screening intervention which in turn may
lead to conservative policy decisions.
We found two studies that assumed a sex difference in the probability of transmission.
It is likely that this assumption is based on analogy to gonorrhoea, [48] although it has
been stated that there is no evidence to suggest that the risk of transmission in chlamydia
differs by direction [56]. The majority of studies in this review based the transmission
probability on a historic cross-sectional study of STI clinic patients which found that
68% of partners of women diagnosed with chlamydia were also infected [56]. This figure
is incorrectly taken to indicate a transmission probability of 0.68. Other authors have dis-
cussed the problems with inferring transmission probability from concordance [56,60].
A per act transmission probability is more difficult to measure than the per partner-
ship probability, but it allows reinfection within a partnership to be modelled (which is
important if repeat infections have a different risk of complications). Katz et al. used
data from a contact tracing programme to estimate that the per act transmission pro-
bability was 0.395 from men to women and 0.323 from women to men, [55] although
they highlight a number of limitations, including assumptions about the distribution of
the transmission probability per act with duration of partnership and uncertainty in the
number of sex acts within a partnership [8,55,60]. Althaus et al. used Quinn’s raw data
in a pair model to estimate that the “true” partnership transmission probability, based
on two partnerships in the last 12 months, is 0.55 (IQR 0.49 - 0.63) and the “true” per
act transmission probability is 0.10 (IQR 0.06 to 0.17), although the limitations with the
raw data remain [60].Conclusion
As model predictions are increasingly used to inform public health policy, there is an
urgent need for further empirical research to reduce parameter uncertainty. Contem-
porary estimates could be obtained or improved by undertaking research including sur-
veys to estimate treatment seeking behaviour, mathematical modelling to improve
estimates of the duration of infection and concordance studies within screening pro-
grammes (in the absence of expedited partner therapy) to estimate the risk of transmis-
sion. In the meantime, authors should use the highest quality contemporary evidence to
inform their parameter values, clearly document their assumptions and make appropriate
use of sensitivity analysis. This will help to make models more transparent and increase
their utility to policy makers.
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